top of page


The funds received through Ryan's Quest are directed, in full, to Duchenne muscular dystrophy research. Ryan's Quest bases all decisions regarding the awarding of funds to research projects, after the project is submitted through a rigorous and transparent review process.

We also collaborate with other non-profit organizations which have similar goals to that of Ryan's Quest concerning current and promising advances being made in Duchenne research. These organizations also have scientific advisors who specialize in the field of DMD to determine the validity and potential of a given project.

Ryan’s Quest Policy on Donated Funds-Ryan’s Quest, Inc. contributes 100% of proceeds for programs, grants, and projects that support its mission to provide and appropriate funds that benefit the community for which it serves. Funds are not to be used for institutional, administrative, overhead, or indirect costs, only direct patient care or research. Ryan's Quest does not support tuition or other education related fees. 

Total funding to date


Please reload

Collaboration grant with Charley's Fund to focus on four initiatives.


 1-A collaborative effort to improve the “gateway to the
clinic.” Brings together experts to optimize preclinical models and methods to
better predict which treatments will benefit patients.

 2- A novel outcome measure using video scales designed to measure quality of
movement in patients with DMD. The tool is being refined and vetted for use in
clinical trials.

 3-Electrical Impedance Myography-  A hand-held device that measures muscle
integrity using electrical signals. The device is being optimized and vetted for use
as an outcome measure in DMD clinical trials.

 4- A potential clinical study that uses video scales
and EIM in patients initiating steroid treatment to help evaluate the two measures’
sensitivity to treatment effect.

Osteoprotegerin Validation


Validate muscle protection effect of osteoprotegerin (OPG) in the MDX model of Duchenne muscular dystrophy

University of Missouri | Dongsheng Duan Ph.D., Program Director

"Shifting Burden of Disease Study"


This project will help accelerate drug development in Duchenne and help patients and caregivers communicate the most burdensome aspects of their disease and how it affects their daily lives in a rigorous and quantitative manner.

Jett Foundation

Montelukast as Potential Therapy for Duchenne Muscular Dystrophy


Evaluation of the anti-inflammatory drug montelukast as a potential therapy for Duchenne Muscular Dystrophy

University of Missouri | Dongsheng Duan Ph.D., Program Director

Kennedy Krieger Institute’s Center for Genetic Muscle Disorders


Screening of small molecules and drugs from the Johns Hopkins Clinical Compound Library, using human myoblasts derived from iPSCs from patients with Duchenne.

Kennedy Krieger Institute | Kathryn Wagner M.D, Ph.D | Gabsang Lee Ph.D.

Osteoprotegerin (OPG)


Drug development support for Osteoprotegerin (OPG) for treatment of Duchenne muscular dystrophy.

DMD Therapeutics

Combination Studies of Quercetin & Nicotinamide Riboside


 with a Steroid and Ace Inhibitor

Iowa State University     ||     University of Montana

Joshua Selsby PhD     ||     John Quindry PhD

Osteoprotegerin (OPG)


Preclinical studies to determine the effect of osteoprotogerin, alone or in combination with beta agonists or glucocorticoids, on muscle health in models of Duchenne muscular dystrophy

University of Laval Quebec, Canada | Jerome Frenette Ph.D

Boston Children's Hospital/Harvard Medical School


Screening of several commonly used and safe serotonin modulators to determine their ability to prevent and correct muscle degeneration which the goal to identify the best candidate and to bring to a clinical trial in boys with Duchenne.

Dr Louis Kunkel (co-discovered the mutation that causes Duchenne)

Support for TREAT-NMD Advisory Committee for Therapeutics (TACT)


Support for TREAT-NMD Advisory Committee for Therapeutics (TACT)

Clinical Trial Research Personnel


Mass General Hospital for Children

Brian Tseng MD/PhD

Biglycan (Utrophin Upregulator)


Brown University/PPMD

Justin Fallon PhD

CombinatoRx-Compound Screen


Charley's Fund


Project Catalyst


University of Pennsylvania/PPMD

Lee Sweeney PhD

Osteopontin (Anti-fibrotic)



Melissa Spencer PhD

Clinical Outcomes Measures for use in Clinical Trials Initiative


Children's National Medical Center/


Children's Nationwide

Exon Skipping screening


University of North Carolina/

Cure Duchenne

Qi Long Lu MD/PhD

Biophysical Characterization of Truncated Dystrophin


University of Minnesota

James Ervasti PhD

Duchenne Dashboard - Phases 1, 2, and 3



Carlo Rago PhD

Travel support for REVERSE-DBMD trial


Kennedy Krieger Institute /

Johns Hopkins

Kathryn Wagner MD/PhD

Nutraceutical (THI), Skeletal Muscle Function


University of Washington

Hannele Ruohola-Baker PhD

Duchenne Dashboard - Phase 4



Carlo Rago PhD

Carmeseal (P188), Cardiac and Skeletal Muscle Function


Phrixus Pharma/

Coalition Duchenne

Bruce Markham PhD

Preparation of Halofuginone for Phase I/II Clinical Trial


Halo Therapeutics

Marc Blaustein CEO

Duchenne Dashboard - Phases 5 and 6



Carlo Rago PhD

Development of Dystrophin Independent Therapy


Boston Children's Hospital/

Jett Foundation

Louis Kunkel PhD

Nutraceutical (THI), Skeletal Muscle Function


University of Minnesota

Dawn Lowe PhD

Nutraceutical (Quercetin) Respiratory and Cardiac Function


Iowa State University

Joshua Selsby PhD

Anti-fibrotic (Relaxin) Skeletal Muscle and Diaphram Histology,


University of Washington

Jeffrey Chamberlain PhD

Halofuginone Phase II Clinical Trial


Halo Therapeutics

Marc Blaustein CEO

Duchenne Muscular Dystrophy Research Conference (Portland, Oregon)



Chris James

New Biomarkers for Duchenne Muscular Dystrophy


Children's Hospital Oakland/Race MD

Julie Saba MD/PhD

Preclinical testing of a PDE9 inhibitor in mdx5cv mice


Boston Children's Hospital/

Jett Foundation  

Louis Kunkel PhD

Nutraceutical (Quercetin) Muscle Function, Cellular Injury, and Bone Loss


Iowa State University, Auburn

University, and The University

of Pennsylvania

Joshua Selsby PhD

Assessing the therapeutic impact of cannabidiol on muscle structure and function


University of Reading/

Harrison's Fund

Keith Foster PhD

Development of SC-Prorelaxin for the Treatment of Duchenne muscular dystrophy


University of Washington &


Jeffrey Chamberlain PhD Ronald Berenson MD

Follistatin Gene Therapy


Childrens's Nationwide Network

Jerry Mendell MD/PhD

VBP 15 Clinical Trial


 ReveraGen Biopharma

Eric Hoffman, Ph.D

Modulating the S1P pathway to treat Duchenne


Children's Hospital & Research Hospital at Oakland

Julie Saba MD,Ph.D

Please reload

bottom of page